Thursday, February 14, 2013
Researchers at the Massachusetts Institute of Technology have
mouse data showing that the cholesterol drug lovastatin can correct fragile X syndrome.1
The findings add to a growing list of unconventional strategies for treating
this common form of mental retardation.
Bear's team strung together prior evidence to formulate the
hypothesis that statins could help treat fragile X.
Statin' the case
The findings suggest statins could fit
into to a treatment regimen for fragile X syndrome, but it is unclear whether
the compounds could work as monotherapy or as adjuncts to other
Osherovich, L. SciBX 6(6); doi:10.1038/scibx.2013.129
Published online Feb. 14, 2013
1. Osterweil, E.K. et
al. Neuron; published online Jan. 23, 2013;
Contact: Mark F. Bear, Massachusetts Institute of Technology, Cambridge,
2. Bhakar, A.L. et al.
Annu. Rev. Neurosci. 35, 417-443 (2012)
J.K. & Laufs, U. Annu. Rev. Pharmacol. Toxicol. 45, 89-118
4. Osterweil, E.K. et
al. J. Neurosci. 30, 15616-15627 (2012)
AND INSTITUTIONS MENTIONED
Afraxis Inc., La Jolla, Calif.
Genentech Inc., South San Francisco, Calif.
Howard Hughes Medical Institute, Chevy Chase, Md.
Massachusetts Institute of Technology, Cambridge, Mass.
Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
Seaside Therapeutics Inc., Cambridge, Mass.